Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial

Annals of Oncology

Volumn 22, Issue 4, 2011, Pages 857-862

  Eastell, R ^a   Adams, J ^b   Clack, G ^c   Howell, A ^b   Cuzick, J ^d   Mackey, J ^e   Beckmann, M W ^f   Coleman, R E ^g  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Anastrozole; Aromatase inhibitors; Bone; Bone mineral density; Breast cancer; Tamoxifen

Indexed keywords

ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; TAMOXIFEN;

ARTICLE; BONE DENSITY; BREAST CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY CANCER; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MONOTHERAPY; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79953320008     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq541     Document Type: Article

References (29)

1. Eastell R. Aromatase inhibitors and bone. J Steroid Biochem Mol Biol 2007; 106: 157-161.
2. McCloskey E. Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 2006; 42: 1044-1051.
3. Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park) 2005; 19: 651-658.
4. Brufsky AM. Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors. Clin Breast Cancer 2007; 8 (Suppl 1): S22-S34.
5. Perez EA. Safety of aromatase inhibitors in the adjuvant setting. Breast Cancer Res Treat 2007; 105 (Suppl 1): 75-89.
6. Buzdar A, Chlebowski R, Cuzick J et al. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr Med Res Opin 2006; 22: 1575-1585.
7. Dowsett M, Cuzick J, Ingle J et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28: 509-518.
8. Eastell R, Adams JE, Coleman RE et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008; 26: 1051-1057.
9. Brufsky AM. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist 2008; 13: 187-195.
10. Chowdhury S, Pickering LM, Ellis PA. Adjuvant aromatase inhibitors and bone health. J Br Menopause Soc 2006; 12: 97-103.
11. Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 1998; 83: 1158-1162.
12. Eastell R, Hannon RA, Cuzick J et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006; 21: 1215-1223.
13. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.
14. The ATAC Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
15. Coates AS, Keshaviah A, Thürlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486-492.
16. Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369: 559-570.
17. Coleman RE, Banks LM, Girgis SI et al. Skeletal effects of exemestane on bonemineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007; 8: 119-127.
18. McCloskey EV, Hannon RA, Lakner G et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer 2007; 43: 2523-2531.
19. Lønning PE, Geisler J, Krag LE et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005; 23: 5126-5137.
20. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-1583.
21. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology V.2. 2008. Breast Cancer. http://www.nccn.org/ (February 2010, date last accessed).
22. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23: 619-629.
23. Hadji P, Body JJ, Aapro MS et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008; 19: 1407-1416.
24. Reid DM, Doughty J, Eastell R et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008; 34: S3-S18.
25. Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Semin Oncol 2006; 33: S13-17.
26. Theriault RL. Strategies to prevent chemotherapy-induced bone loss in women with breast cancer. Clin Breast Cancer 2005; 5 (Suppl): S63-S70.
27. Bundred NJ, Campbell ID, Davidson N et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 2008; 112: 1001-1010.
28. Confavreux CB, Fontana A, Guastalla JP et al. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 2007; 41: 346-352.
29. Van Poznak C, Hannon R, Clack G. Managing cancer treatment-induced bone loss: 24-month results from the study of anastrozole with the bisphosphonate risedronate (SABRE). Presented at the San Antonio Breast Cancer Symposium, San Antonia, TX, 10-14 December 2008.